Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
3.
POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION
A ribonucleic acid comprising two non-natural pre-miRNA sequences, wherein each pre-miRNA sequence comprises a guide miRNA that inhibits the expression of an immune checkpoint protein. The pre-miRNA sequences may target a different gene or target a different regions of the same gene. A deoxyribonucleic acid encoding the aforementioned ribonucleic acid. The deoxyribonucleic acid may further encode a protein such as a chimeric antigen receptor, a cytokine, a cell tag, and/or an immune checkpoint inhibitor. A vector comprising the aforementioned ribonucleoic acid or the aforementioned deoxyribonucleic acid. A method for modifying the expression of a gene in a cell, wherein the method comprises introducing the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid to the cell. A method for producing a genetically-engineered cell, wherein the method comprises introducing the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid to the cell. A genetically-modified cell comprising the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid. A composition comprising the aforementioned ribonucleic acid or the aforementioned deoxynbonucleic acid. A kit comprising the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid. A method of treating a disease or disorder in a subject, comprising administering the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid to the subject. A method of treating a disease or disorder in a subject, comprising administering the aforementioned cell to the subject. The use of the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid in the manufacture of a medicament for modifying the expression of a gene. The use of the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid in the manufacture of a medicament for the treatment of a disease or disorder in a subject.
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
A chimeric antigen receptor (CAR), for example a CD19-specific CAR, capable of targeting an antigen expressed on disease-associated cells, such as tumor cells. A polynucleotide encoding the CAR and, optionally: i) an miRNA silencer module capable of inhibiting the expression of an immune checkpoint protein (e.g., PD-1); ii) a cytokine (e.g., membrane-bound IL-15); and/or a cell tag (e.g., a HER-1 kill switch). A vector comprising the polynucleotide. A modified immune effector cell comprising the CAR, polynucleotide, or vector. Compositions and kits comprising the CAR, polynucleotide, vector, and/or modified immune effector cell. Use of the CAR, polynucleotide, vector, and/or modified immune effector cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for treating a subject with a disease or disorder, comprising administering the CAR, polynucleotide, vector, and/or modified immune effector cell to a subject in need thereof.
iiyamamaltonmalton). The construct may further comprise a liver-specific promoter. A vector, such as a gorilla adenoviral vector, comprising the genetic construct. A method of treating a disease or disorder, such as COPD, bronchiectasis, neonatal cholestasis, cirrhosis, fibrosis, and hepatocellular carcinoma, comprising administering a therapeutically effective amount of the aforementioned vector. A use of the genetic construct in the manufacture of a medicament for use in treating a disease or disorder. A composition comprising the genetic construct. A kit comprising the genetic construct.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV-associated disorders and pathologies, such as HPV molecular vaccines targeting HPV6- and HPV11-associated recurrent respiratory papillomatosis (RRP).
Multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV-associated disorders and pathologies, such as HPV molecular vaccines targeting HPV16-, HPV18-, and HPV-45-associated pathologies.
Multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV-associated disorders and pathologies, such as HPV molecular vaccines targeting HPV16-, HPV18-, and HPV-45-associated pathologies.
Multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV-associated disorders and pathologies, such as HPV molecular vaccines targeting HPV6- and HPV11-associated recurrent respiratory papillomatosis (RRP).
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
Promoting public awareness of issues and risks relating to
recurrent respiratory papillomatosis and the testing for and
treatment of recurrent respiratory papillomatosis.
21.
RECURRENT RESPIRATORY PAPILLOMATOSIS AWARENESS GIVING VOICE TO INSPIRE CHANGE
Promoting public awareness of issues and risks relating to
recurrent respiratory papillomatosis and the testing for and
treatment of recurrent respiratory papillomatosis.
Promoting public awareness of issues and risks relating to
recurrent respiratory papillomatosis and the testing for and
treatment of recurrent respiratory papillomatosis.
Promoting public awareness of issues and risks relating to
recurrent respiratory papillomatosis and the testing for and
treatment of recurrent respiratory papillomatosis.
Promoting public awareness of issues and risks relating to
recurrent respiratory papillomatosis and the testing for and
treatment of recurrent respiratory papillomatosis.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; therapeutic vaccines; therapeutic vaccines for the
treatment of Human Papilloma Virus (HPV) and HPV-related
disorders and diseases, in particular disorders and diseases
caused by one or both of HPV 6 and HPV 11, including
Recurrent Respiratory Papillomatosis (RRP); pharmaceutical
preparations and substances for the treatment of Human
Papilloma Virus (HPV) and HPV-related disorders and
diseases, in particular disorders and diseases caused by one
or both of HPV 6 and HPV 11, including Recurrent Respiratory
Papillomatosis (RRP).
26.
Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
Provided herein are vectors comprising a polycistronic expression casstte comprising a polynucleotide that encodes a CD 19 specific chimeric antigen receptor, a polynucleotide that encodes a cytokine, and a polynucleotide that encodes a marker protein, wherein the polynucleotide that encodes the CD 19-specific chimeric antigen receptor and the polynucleotide that encodes the cytokine coding sequence are separated by a polynucleotide sequence that comprises an F2A element, and wherein the polynucleotide sequence that encodes the cytokine and the polynucleotide sequence that encodes the marker protein are separated by a polynucleotide sequence that comprises a T2A element.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
(1) Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis.
(1) Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis.
(1) Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis.
30.
RECURRENT RESPIRATORY PAPILLOMATOSIS AWARENESS GIVING VOICE TO INSPIRE CHANGE
(1) Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis.
31.
MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Vaccines for humans; therapeutic vaccines for humans; therapeutic vaccines for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP); pharmaceutical preparations and substances for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP)
34.
Human Papilloma Virus Vaccines and Uses of the Same for HPV Associated Diseases
Provided herein are multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV associated disorders and pathologies; such as HPV molecular vaccines targeting HPV6 and HPV11 associated pathologies.
Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-β trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis
Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis
39.
RECURRENT RESPIRATORY PAPILLOMATOSIS AWARENESS GIVING VOICE TO INSPIRE CHANGE
Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis
Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis
Promoting public awareness of issues and risks relating to recurrent respiratory papillomatosis and the testing for and treatment of recurrent respiratory papillomatosis
42.
POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A ribonucleic acid comprising two non-natural pre-miRNA sequences, wherein each pre-miRNA sequence comprises a guide miRNA that inhibits the expression of an immune checkpoint protein. The pre-miRNA sequences may target a different gene or target a different regions of the same gene. A deoxyribonucleic acid encoding the aforementioned ribonucleic acid. The deoxyribonucleic acid may further encode a protein such as a chimeric antigen receptor, a cytokine, a cell tag, and/or an immune checkpoint inhibitor. A vector comprising the aforementioned ribonucleoic acid or the aforementioned deoxyribonucleic acid. A method for modifying the expression of a gene in a cell, wherein the method comprises introducing the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid to the cell. A method for producing a genetically-engineered cell, wherein the method comprises introducing the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid to the cell. A genetically-modified cell comprising the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid. A composition comprising the aforementioned ribonucleic acid or the aforementioned deoxynbonucleic acid. A kit comprising the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid. A method of treating a disease or disorder in a subject, comprising administering the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid to the subject. A method of treating a disease or disorder in a subject, comprising administering the aforementioned cell to the subject. The use of the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid in the manufacture of a medicament for modifying the expression of a gene. The use of the aforementioned ribonucleic acid or the aforementioned deoxyribonucleic acid in the manufacture of a medicament for the treatment of a disease or disorder in a subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 25/00 - Drugs for disorders of the nervous system
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Disclosed herein are methods and compositions including antigen-binding polypeptides comprising a stalk region and a stalk extension region. In some cases, the antigen-binding compositions comprising the stalk extension region has increased expression on a cell surface and, in some cases, has increased antigen-binding efficiency. A subject antigen binding polypeptide can be a chimeric antigen receptor (CAR).
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; therapeutic vaccines; therapeutic vaccines for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP); pharmaceutical preparations and substances for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; therapeutic vaccines; therapeutic vaccines for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP); pharmaceutical preparations and substances for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; therapeutic vaccines; therapeutic vaccines for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP); pharmaceutical preparations and substances for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; therapeutic vaccines; therapeutic vaccines for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP); pharmaceutical preparations and substances for the treatment of Human Papilloma Virus (HPV) and HPV-related disorders and diseases, in particular disorders and diseases caused by one or both of HPV 6 and HPV 11, including Recurrent Respiratory Papillomatosis (RRP)
Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of complex diseases; Medical research in the field of immunotherapy. Medical services, namely, providing medical therapy treatments for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseases.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemicals, biochemicals and reagents for use in industry and science; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting gene expression; kits consisting primarily of proteins for regulating, modifying or restricting gene expression Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders Scientific research and development services in the field of medicine, pharmacology, immunology, biochemistry, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncology, rare diseases, metabolic disorders, and infectious diseases which are under development or have completed development; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use Medical services; Medical services, namely, genetic engineering, biopharmaceuticals and gene therapy services; Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders; Medical services, namely, providing medical therapy treatments which are under development or have completed development for patients in the fields of oncology, rare diseases, metabolic disorders, and infectious diseases Technology transfer services, namely, licensing of intellectual property
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Scientific research and development services in the field of medicine, pharmacology, immunology, biochemistry, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncology, rare diseases, metabolic disorders, and infectious diseases which are under development or have completed development; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use Medical services; Medical services, namely, genetic engineering, biopharmaceuticals and gene therapy services; Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders; Medical services, namely, providing medical therapy treatments which are under development or have completed development for patients in the fields of oncology, rare diseases, metabolic disorders, and infectious diseases Technology transfer services, namely, licensing of intellectual property
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of complex diseases; medical research in the field of immunotherapy Medical services, namely, providing medical therapy treatments for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseases
An electroporation buffer comprising: a solvent; a sugar; a chloride salt; and a buffering agent. In certain embodiments: the solvent is water; the sugar is glucose or mannitol; the chloride salt is potassium chloride (KCl) or magnesium chloride (MgCl2); and the buffering agent is sodium phosphate, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and/or dimethyl sulfoxide (DMSO). A method of electroporation, the method comprising applying an electric current to a suspension comprising: isolated eukaryotic cells; a biological material that is exogenous to the cells; and the aforementioned buffer. A recombinant cell produced using such a method. An electroporation apparatus comprising: one or more chambers; one or more pairs of electrodes configured to generate electric fields within the one or more chambers, wherein each electric field corresponds to one chamber; and a flow channel. A method for electroporation comprising utilizing the aforementioned electroporation apparatus.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
22); and the buffering agent is sodium phosphate, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and/or dimethyl sulfoxide (DMSO). A method of electroporation, the method comprising applying an electric current to a suspension comprising: isolated eukaryotic cells; a biological material that is exogenous to the cells; and the aforementioned buffer. A recombinant cell produced using such a method. An electroporation apparatus comprising: one or more chambers; one or more pairs of electrodes configured to generate electric fields within the one or more chambers, wherein each electric field corresponds to one chamber; and a flow channel. A method for electroporation comprising utilizing the aforementioned electroporation apparatus.
C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
A non-naturally occurring polynucleotide encoding a miRNA that inhibits the expression of an immune checkpoint protein. The polynucleotide may further encode a chimeric receptor, a cytokine, and/or a cell tag. A vector comprising the aforementioned polynucleotide. A modified immune effector cell comprising the aforementioned polynucleotide. Compositions and kits comprising the aforementioned polynucleotide and/or cell. A method for treating a subject suffering from a disease or disorder, comprising administering the aforementioned cell to a subject in need thereof. The use of the aforementioned cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for the detection of a disease or disorder associated with the overexpression of an antigen in a subject. A method for the treatment of a disease or disorder comprising the serial administration of polynucleotides encoding a chimeric antigen receptor or a cell comprising the same.
A non-naturally occurring polynucleotide encoding a miRNA that inhibits the expression of an immune checkpoint protein. The polynucleotide may further encode a chimeric receptor, a cytokine, and/or a cell tag. A vector comprising the aforementioned polynucleotide. A modified immune effector cell comprising the aforementioned polynucleotide. Compositions and kits comprising the aforementioned polynucleotide and/or cell. A method for treating a subject suffering from a disease or disorder, comprising administering the aforementioned cell to a subject in need thereof. The use of the aforementioned cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for the detection of a disease or disorder associated with the overexpression of an antigen in a subject. A method for the treatment of a disease or disorder comprising the serial administration of polynucleotides encoding a chimeric antigen receptor or a cell comprising the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A non-naturally occurring polynucleotide encoding a miRNA that inhibits the expression of an immune checkpoint protein. The polynucleotide may further encode a chimeric receptor, a cytokine, and/or a cell tag. A vector comprising the aforementioned polynucleotide. A modified immune effector cell comprising the aforementioned polynucleotide. Compositions and kits comprising the aforementioned polynucleotide and/or cell. A method for treating a subject suffering from a disease or disorder, comprising administering the aforementioned cell to a subject in need thereof. The use of the aforementioned cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for the detection of a disease or disorder associated with the overexpression of an antigen in a subject. A method for the treatment of a disease or disorder comprising the serial administration of polynucleotides encoding a chimeric antigen receptor or a cell comprising the same.
Provided herein are multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV associated disorders and pathologies; such as HPV molecular vaccines targeting HPV6 and HPVll associated pathologies.
Provided herein are multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV associated disorders and pathologies; such as HPV molecular vaccines targeting HPV6 and HPVll associated pathologies.
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-ß trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
69.
ROR-1 specific chimeric antigen receptors and uses thereof
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/00 - Drugs for disorders of the nervous system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Electroporation is a technique in which an electrical field is applied to cells in order to increase the permeability of the cell membrane. This allows for chemicals, drugs, and/or macromolecules such as proteins and nucleic acids to be introduced into the cells. Embodiments relate to an electroporation apparatus. The electroporation apparatus comprises: a plurality of chambers configured to store a plurality of cells during an electroporation process; a plurality of electrodes configured to generate a plurality of electric fields within the plurality of chambers during the electroporation process, each electric field of the plurality of electric fields corresponding to one chamber of the plurality of chambers; a flow channel configured to transport the plurality cells during a cell collection process after the electroporation process; and a plurality of valves connecting the plurality of chambers to the flow channel.
Electroporation is a technique in which an electrical field is applied to cells in order to increase the permeability of the cell membrane. This allows for chemicals, drugs, and/or macromolecules such as proteins and nucleic acids to be introduced into the cells. Embodiments relate to an electroporation apparatus. The electroporation apparatus comprises: a plurality of chambers configured to store a plurality of cells during an electroporation process; a plurality of electrodes configured to generate a plurality of electric fields within the plurality of chambers during the electroporation process, each electric field of the plurality of electric fields corresponding to one chamber of the plurality of chambers; a flow channel configured to transport the plurality cells during a cell collection process after the electroporation process; and a plurality of valves connecting the plurality of chambers to the flow channel.
Electroporation is a technique in which an electrical field is applied to cells in order to increase the permeability of the cell membrane. This allows for chemicals, drugs, and/or macromolecules such as proteins and nucleic acids to be introduced into the cells. Embodiments relate to an electroporation apparatus. The electroporation apparatus comprises: a plurality of chambers configured to store a plurality of cells during an electroporation process; a plurality of electrodes configured to generate a plurality of electric fields within the plurality of chambers during the electroporation process, each electric field of the plurality of electric fields corresponding to one chamber of the plurality of chambers; a flow channel configured to transport the plurality cells during a cell collection process after the electroporation process; and a plurality of valves connecting the plurality of chambers to the flow channel.
Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-β trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF- trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
79.
ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
Disclosed herein are methods and compositions including antigen-binding polypeptides comprising a stalk region and a stalk extension region. In some cases, the antigen-binding compositions comprising the stalk extension region has increased expression on a cell surface and, in some cases, has increased antigen-binding efficiency. A subject antigen binding polypeptide can be a chimeric antigen receptor (CAR).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed herein are methods and compositions including antigen-binding polypeptides comprising a stalk region and a stalk extension region. In some cases, the antigen-binding compositions comprising the stalk extension region has increased expression on a cell surface and, in some cases, has increased antigen-binding efficiency. A subject antigen binding polypeptide can be a chimeric antigen receptor (CAR).
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
89.
Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
91.
CELL TAGS COMPRISING A TRUNCATED NON-IMMUNOGENIC HER1 POLYPEPTIDE
Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer
93.
Modulating expression of polypeptides via new gene switch expression systems
Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.
A61P 25/00 - Drugs for disorders of the nervous system
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Chemicals, biochemicals and reagents for use in industry and science, namely, scientific research purposes, laboratory use, manufacture of pharmaceuticals; chemicals, biochemicals and reagents, namely, proteins, nucleic acids, viral vectors and non-viral vectors for regulating, modifying or restricting gene expression.
(2) Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders. (1) Scientific research and development services in the field of medicine, pharmacology, immunology, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare, namely, immunooncology, autoimmune disorders, infectious diseases, otology; Therapeutic research of treatment in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, otology, and cardiovascular disease; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use
(2) Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; Medical services, namely, providing medical therapy treatments for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, otology, and cardiovascular diseases; Medical services, namely, genetic engineering, biopharmaceutical treatments and gene therapy services
(3) Technology transfer services, namely, licensing of intellectual property
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Chemicals, biochemicals and reagents for use in industry and science, namely, scientific research purposes, laboratory use, manufacture of pharmaceuticals; chemicals, biochemicals and reagents, namely, proteins, nucleic acids, viral vectors and non-viral vectors for regulating, modifying or restricting gene expression.
(2) Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders. (1) Scientific research and development services in the field of medicine, pharmacology, immunology, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare, namely, immunooncology, autoimmune disorders, infectious diseases, otology; Therapeutic research of treatment in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, otology, and cardiovascular disease; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use.
(2) Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; Medical services, namely, providing medical therapy treatments for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, otology, and cardiovascular diseases; Medical services, namely, genetic engineering, biopharmaceutical treatments and gene therapy services.
(3) Technology transfer services, namely, licensing of intellectual property
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemicals, biochemicals and reagents for use in industry and science; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting gene expression; kits consisting primarily of proteins for regulating, modifying or restricting gene expression Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders Scientific research and development services in the field of medicine, pharmacology, immunology, biochemistry, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular disease which are under development or have completed development; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use Medical services; Medical services, namely, genetic engineering, biopharmaceuticals and gene therapy services; Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; Medical services, namely, providing medical therapy treatments which are under development or have completed development for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseases Technology transfer services, namely, licensing of intellectual property
